Recent Updates
Recently added Catalysts
GILD Positive Sentiment

Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention

Wednesday, September 16, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Gilead Sciences has expanded its royalty-free licensing agreements for lenacapavir to include a once-yearly formulation for HIV prevention. This initiative aims to enhance global access to pre-exposure prophylaxis (PrEP) in 120 high-incidence countries, primarily targeting low- and lower-middle-income regions. The agreements will facilitate manufacturing readiness and technology transfer.

Market Sentiment Analysis

POSITIVE FACTORS

  • Expansion of licensing agreements for lenacapavir.
  • Focus on global access to HIV prevention.
  • Support for manufacturing readiness in high-incidence countries.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
1.6%
average across 15 past catalysts
Lead asset
Lenacapavir
Phase 3 · HIV Infections

Full Press Release Details

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreements cover 120 high-incidence countries (which are primarily low- and lower-middle-income) and will support manufacturing readiness, technology transfer and future supply planning while the

Frequently Asked Questions

What is lenacapavir?

Lenacapavir is an investigational drug for HIV prevention, used as pre-exposure prophylaxis.

How many countries are included in Gilead's agreements?

The agreements cover 120 high-incidence countries.

What is the purpose of the licensing agreements?

The agreements aim to support manufacturing readiness and technology transfer for lenacapavir.

What type of income countries are targeted?

The agreements primarily target low- and lower-middle-income countries.

ShareAdd on Google
Tags: GILD Viatris Investor Conferences Healthcare Gilead lenacapavir HIV prevention PrEP licensing agreements
Last updated: Sep 16, 2026

Biotech snapshot

Cash runway
$3179M liquidity · $0M/mo burn
Low dilution risk
Lead asset
LenacapavirPhase 3
HIV Infections →

Catalyst track record

+24%
best trade around GILD's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for GILD.

See every catalyst's timing & PoA →